Trial Profile
A Phase IIb, Multi-National, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Efficacy of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS) (BENEFIT-ALS)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 11 Aug 2022
Price :
$35
*
At a glance
- Drugs Tirasemtiv (Primary) ; Riluzole
- Indications Amyotrophic lateral sclerosis
- Focus Therapeutic Use
- Acronyms BENEFIT-ALS
- Sponsors Cytokinetics
- 04 Aug 2022 According to a Cytokinetics media release, the company announced the release of pooled Resource Open-Access ALS Clinical Trials (PRO-ACT) database updated with clinical data from this trial.
- 30 Nov 2017 According to a Cytokinetics media release, retrospective analysis data from EMPOWER, BENEFIT-ALS and Open-Access ALS Clinical Trials (PRO-ACT) database were published in the Journal of the American Medical Association (JAMA) Neurology.
- 30 Nov 2017 Retrospective data was published in a Cytokinetics media release.